These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 8052962)

  • 1. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
    Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S
    Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats.
    Gonda Y; Hirata S; Saitoh K; Aoki Y; Mohri M; Gomi K; Sugihara T; Kiyota T; Yamamoto S; Ishida T
    Thromb Res; 1993 Aug; 71(4):325-35. PubMed ID: 8236161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.
    Wang YX; Wu C; Vincelette J; Martin-McNulty B; Alexander S; Larsen B; Light DR; McLean K
    Thromb Haemost; 2006 Sep; 96(3):317-24. PubMed ID: 16953273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: thrombomodulin associates with free thrombin and is recycled to activate protein c.
    Aritomi M; Watanabe N; Ohishi R; Gomi K; Kiyota T; Yamamoto S; Ishida T; Maruyama I
    Thromb Haemost; 1993 Sep; 70(3):418-22. PubMed ID: 8259541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats.
    Mohri M; Oka M; Aoki Y; Gonda Y; Hirata S; Gomi K; Kiyota T; Sugihara T; Yamamoto S; Ishida T
    Am J Hematol; 1994 Apr; 45(4):298-303. PubMed ID: 8178801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
    Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation.
    Nawa K; Itani T; Ono M; Sakano K; Marumoto Y; Iwamoto M
    Thromb Haemost; 1992 Mar; 67(3):366-70. PubMed ID: 1322570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6,7-Dihydroxy-3-phenylcoumarin inhibits thromboplastin induced disseminated intravascular coagulation.
    Tunali T; Yarat A; Bulut M; Emekli N
    Br J Haematol; 2004 Jul; 126(2):226-30. PubMed ID: 15238144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of disseminated intravascular coagulation (DIC) with all-trans retinoic acid in an endotoxin-induced rat model.
    Aoshima K; Asakura H; Yamazaki M; Saito M; Kumabashiri I; Morishita E; Ontachi Y; Mizutani T; Ichino T; Matsuda T
    Semin Thromb Hemost; 1998; 24(3):227-31. PubMed ID: 9701452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATIII-independence of anticoagulant effect of human urinary soluble thrombomodulin.
    Imada K; Takahashi Y; Hosaka Y; Adachi T; Niina H; Mochizuki H
    Blood Coagul Fibrinolysis; 1999 Dec; 10(8):503-11. PubMed ID: 10636462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats.
    Aoki Y; Ota M; Katsuura Y; Komoriya K; Nakagaki T
    Arzneimittelforschung; 2000 Sep; 50(9):809-15. PubMed ID: 11050697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
    Levi M; Toh CH; Thachil J; Watson HG
    Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
    Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
    Thromb Haemost; 1994 Sep; 72(3):392-6. PubMed ID: 7855790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical relevance of determination of plasma ATIII and alpha 2 PI activities in patients with DIC--application of the molecular markers for the analysis of pathophysiology of DIC].
    Okajima K
    Rinsho Byori; 1994 Jan; 42(1):45-55. PubMed ID: 8107283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotection by recombinant thrombomodulin.
    Taoka Y; Okajima K; Uchiba M; Johno M
    Thromb Haemost; 2000 Mar; 83(3):462-8. PubMed ID: 10744154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrarenal administration of recombinant human soluble thrombomodulin ameliorates ischaemic acute renal failure.
    Ozaki T; Anas C; Maruyama S; Yamamoto T; Yasuda K; Morita Y; Ito Y; Gotoh M; Yuzawa Y; Matsuo S
    Nephrol Dial Transplant; 2008 Jan; 23(1):110-9. PubMed ID: 17804460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of human soluble thrombomodulin on experimental glomerulonephritis.
    Ikeguchi H; Maruyama S; Morita Y; Fujita Y; Kato T; Natori Y; Akatsu H; Campbell W; Okada N; Okada H; Yuzawa Y; Matsuo S
    Kidney Int; 2002 Feb; 61(2):490-501. PubMed ID: 11849389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human antithrombin expressed in Chinese hamster ovary cells shows in vivo efficacy on rat DIC model similarly to plasma-derived antithrombin regardless of different N-glycosylation.
    Hirose M; Tsukada M; Hirayama F; Kubo Y; Kajii M; Mochizuki S; Hamato N; Ohi H
    Thromb Res; 2007; 119(5):631-41. PubMed ID: 16844203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models.
    Asakura H; Ichino T; Yoshida T; Suga Y; Ontachi Y; Mizutani T; Kato M; Ito T; Yamazaki M; Aoshima K; Morishita E; Saito M; Miyamoto KI; Nakao S
    Blood Coagul Fibrinolysis; 2002 Apr; 13(3):233-9. PubMed ID: 11943937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
    Tazawa S; Ichikawa K; Misawa K; Fukuyama J; Hamano S; Miyata H; Sakuragawa N
    Thromb Res; 1995 Dec; 80(5):391-8. PubMed ID: 8588200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.